What lies ahead for the global immunodiagnostics market?

A trend towards personalised medicine is expected to boost the sector’s growth.

The global market for immunodiagnostics is forecasted to rise by $29.5b by 2028 at a compound annual growth rate (CAGR) of approximately 13.64% amidst increasing demand for biomarker-based tests.

Technavio revealed that the sector is driven by a trend towards personalised medicine to provide tailored treatments based on age, gender, and disease severity.

“This approach requires highly sensitive and specific diagnostic tests. Immunodiagnostics delivers this capability, making it a vital component of precision medicine,” the report said.

Meanwhile, immunodiagnostics is considered a crucial area of in vitro diagnostics, focusing on the detection and quantification of antigen-antibody reactions to identify diseases.

This addresses a range of conditions, including HIV, Hepatitis B, Dengue, sexually transmitted infections (STIs), cardiovascular diseases, cancer, gastrointestinal disorders, and chronic illnesses.

Furthermore, these tests are utilised particularly in hospitals and clinics for more accurate diagnosis in the fields of autoimmune disorders, endocrinology, oncology, and pathology.